Sponsors (5)
The bill increases civil remedies and preserves federal obscenity enforcement while removing or restricting FDA-authorized mifepristone access and imposing new criminal and civil risks on providers and manufacturers — trading broader legal remedies and enforcement clarity for substantially reduced medication-abortion access and increased legal and economic burdens on the health system and patients.
People who claim they were harmed by mifepristone for pregnancy termination can sue manufacturers in federal or state court and recover compensatory and punitive damages and attorney's fees, with state-law remedies remaining available.
Pharmacies and manufacturers are given a defined 14-day period to adjust inventories and labeling before approvals are deemed withdrawn, providing a short transition window for hospitals, clinics, and supply chains.
The bill makes the federal legal status of mifepristone explicit, creating clearer statutory footing about its approval/removal.
Millions of patients who would use mifepristone for medication abortion could lose access to an FDA-approved option within 14 days, substantially reducing safe, legal medication abortion access.
Pharmacies, clinics, and individual providers could face criminal or enforcement risk for dispensing or distributing previously approved mifepristone, disrupting care delivery and deterring providers from offering services.
Manufacturers and generic producers face new federal liability exposure and potential loss of ability to lawfully market or distribute mifepristone, risking higher drug prices, supply shortages, and reduced availability for other legitimate medical uses.
Based on analysis of 8 sections of legislative text.
Introduced March 11, 2026 by Joshua David Hawley · Last progress March 11, 2026
Removes federal approval for mifepristone when used to end an intrauterine pregnancy and treats distribution of that drug for that purpose as unlawful 14 days after enactment. It also creates a federal civil cause of action, starting 90 days after enactment, allowing people who suffer bodily or mental harm after using such mifepristone to sue the drug’s manufacturer for compensatory and punitive damages and attorney fees. The law also declares labeling that states mifepristone may be used to terminate pregnancy to be misbranded and preserves an unrelated federal obscenity statute.